Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or


          Standard; Transfer of Listing

On March 30, 2023, Intelligent Medicine Acquisition Corp. (the "Company") received a letter (the "Letter") from the Listing Qualifications division (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has not paid certain fees required by Nasdaq Listing Rule 5250(f) and that the Company will be delisted unless it appeals such determination. As of the date of the Notice, the Company's past due fee balance totaled $140,000. If the Company elects not to appeal, trading of its Class A ordinary shares will be suspended at the opening of business on April 11, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on Nasdaq.

In addition, the Letter stated that the Company was not in compliance with the requirements of the Nasdaq Listing rules set forth in Listing Rule 5450(b)(2)(B), requiring a minimum 1,100,000 Publicly Held Shares. The Staff's determination was based on the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on February 9, 2023, in which the Company disclosed that 20,009,861 shares of Class A common stock exercised their redemption rights in connection with a special meeting of stockholders held on February 8, 2023. The Letter noted that pursuant to Listing Rule 5810(c)(2)(A), non-compliance with Listing Rule 5450(b)(2)(B) serves as an additional and separate basis for delisting.

The Company intends to request a hearing before the Nasdaq Hearings Panel (the "Panel") to appeal the Staff's delisiting determination.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits:



Exhibit                                 Description
104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document).

© Edgar Online, source Glimpses